COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,790 Articles (22,523 medRxiv, 8,267 bioRxiv)

Most recent first Previous |  Page 1194: Articles 11931-11940  | Next

Dual domain recognition determines SARS-CoV-2 PLpro selectivity for human ISG15 and K48-linked di-ubiquitin
Osipiuk, J., Wydorski, P. M., Lanham, B. T., Tesar, C., Endres, M., Engle, E., Jedrzejczak, R., Mullapudi, V., Michalska, K., Fidelis, K., Fushman, D., Joachimiak, A., Joachimiak, L. A.
10.1101/2021.09.15.460543 — Posted: 2021-09-16
Persistent oxidative stress and inflammasome activation in CD14highCD16- monocytes from COVID-19 patients
Lucena Lage, S., Pinheiro Amaral, E., Hilligan, k. L., Laidlaw, E., Rupert, A., Namasivayan, S., Rocco, J., Galindo, F., Kellogg, A., Kumar, P., Poon, R., Wortmann, G. W., Shannon, J. P., Hickman, H. D., Lisco, A., Manion, M., Sher, A., Sereti, I.
10.1101/2021.09.13.21263292 — Posted: 2021-09-16
Reduced levels of convalescent neutralizing antibodies against SARS-CoV-2 B.1+L249S+E484K lineage
Alvarez Diaz, D. A., Laiton Donato, K., Torres Garcia, O. A., Ruiz Moreno, H. A., Franco Munoz, C. E., Beltran, M. A., Mercado Reyes, M., Rueda, M. G., Munoz Ramirez, A. L.
10.1101/2021.09.13.21263430 — Posted: 2021-09-16
Using Artificial Intelligence-based models to predict the risk of Mucormycosis among COVID-19 Survivors: An Experience from India
Syed-Abdul, S., Babu, A. S., Bellamkonda, R. S., Itumalla, R., Acharyulu, G., Krishnamurthy, S., Ramana, Y. V. S., Mogilicharla, N., Malwade, S., Li, Y.-C.
10.1101/2021.09.13.21263511 — Posted: 2021-09-16
Detailed Overview of the Buildout and Integration of an Automated High-Throughput CLIA Laboratory for SARS-CoV-2 Testing on a Large Urban Campus
Landaverde, L., McIntyre, D., Robson, J., Fu, D., Ortiz, L., Chen, R., Oliveira, S. M. D., Fan, A., Barrett, A., Burgay, S. P., Choate, S., Corbett, D., Doucette-Stamm, L., Gonzalez, K., Hamer, D. H., Huang, L., Huval, S., Knight, C., Lindquist, D., Lockard, K., Macdowell, T. L., Mauro, E., McGinty, C., Miller, C., Monahan, M., Moore, R., Platt, J., Roy, J., Schroeder, T., Tolan, D. R., Zaia, A., Brown, R. A., Waters, G., Densmore, D., Klapperich, C. M.
10.1101/2021.09.13.21263214 — Posted: 2021-09-16
Spread of SARS-CoV-2 Delta variant infections bearing the S:E484Q and S:T95I mutations in July and August 2021 in France
Verdume, L., Danesh, G., Trombert, S., Sofonea, M. T., Noel, V., Foulongne, V., Montes, B., TUAILLON, E., Haim-Boukobza, S., Roquebert, B., Alizon, S.
10.1101/2021.09.13.21263371 — Posted: 2021-09-16 Discussion: Onsite
Severe Acute Respiratory Syndrome Coronavirus-2 seropositivity in South-central Uganda, during 2019 - 2021
Ssuuna, C., Galiwango, R. M., Kankaka, E. N., Kagaayi, J., Ndyanabo, A., Kigozi, G., Nakigozi, G., Lutalo, T., Ssekubugu, R., Wasswa, J. B., Mayinja, A., Nakibuuka, M. C., Jamiru, S., Oketch, J. B., Muwanga, E., Chang, L. W., Grabowski, M. K., Wawer, M., Gray, R., Anderson, M., Stec, M., Cloherty, G., Laeyendecker, O., Reynolds, S. J., Quinn, T. C., Serwadda, D. M.
10.1101/2021.09.13.21263414 — Posted: 2021-09-16
Efficacy of two doses of COVID-19 vaccine against severe COVID-19 in those with risk conditions and residual risk to the clinically extremely vulnerable: the REACT-SCOT case-control study
McKeigue, P. M., McAllister, D., Robertson, C., Hutchinson, S. J., McGurnaghan, S., Stockton, D., Colhoun, H. M.
10.1101/2021.09.13.21262360 — Posted: 2021-09-16 Discussion: Onsite
mRNA COVID-19 Vaccination and Development of CMR-confirmed Myopericarditis
Kafil, T., Lamacie, M. M., Chenier, S., Taggart, H., Ghosh, N., Dick, A., Small, G., Liu, P., Beanlands, R. S., Mielniczuk, L., Birnie, D., Crean, A. M.
10.1101/2021.09.13.21262182 — Posted: 2021-09-16 Discussion: Onsite | Offsite
Factors Influencing The First and Second Peak of COVID-19 Global Cases: A Survival Analysis
Oshan, Y. A., Zainab, B., Bandyopadhyay, D., Rahaman Khan, H.
10.1101/2021.09.13.21263497 — Posted: 2021-09-16 Discussion: Onsite

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).